State Medicaid programs will also have access to these medications at these prices. CNBC reported on November 6, 2025, that Medicare will start covering obesity drugs for some patients for the first time starting mid-2026, a long-awaited move that could broaden the market for the medicines and spur more private insurers to cover them. A senior administration official explained the rationale to CNBC: We are constraining the access for patients that will benefit clinically from it, weve worked very hard to strike a balance between broad access that just makes sure to capture patients that will benefit clinically. Documentation of these qualifying conditions will be essential for coverage approval
This provides a solid rationale for considering a switch if maximizing weight loss is a key objective, particularly if results with semaglutide have plateaued
These drugs should not be sold as cosmetic shortcuts, longevity hacks, or quick fixes
Some lost weight quickly, while others lost it slowly
Patients frequently notice decreased hunger, earlier satiety, diminished cravings, increased energy for physical activities, and enhancements in blood sugar, cholesterol, and blood pressure